Effect of Remazolam on Anesthesia Recovery in Patients Undergoing Fundus Surgery

Launched by SICHUAN PROVINCIAL PEOPLE'S HOSPITAL · Jan 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called remazolam to see how it affects recovery after anesthesia in patients undergoing fundus surgery, which is a type of eye surgery. The goal is to help doctors choose better anesthesia options for this specific procedure. The trial is not yet open for participants, and it plans to include adults aged 18 to 65 who are generally healthy (classified as ASA I-II). Participants should be scheduled for surgery lasting about 30 to 120 minutes and have a body mass index (BMI) between 18 and 30.

To take part in the trial, patients cannot have certain health conditions, such as severe heart or lung diseases, or a history of drug abuse. If eligible, participants will receive remazolam during their surgery and will be monitored to see how well they recover afterward. It's important to know that this trial aims to improve anesthesia practices, which could lead to better experiences for patients in the future. If you're interested in learning more or think you might qualify, please reach out to the clinical trial team for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. ASA I-II, patients
• • 2. aged 18-65 years old;
• • 3. Fundus surgery to be performed under general anesthesia ;
• • 4. The expected duration of surgery is about 30-120 min ;
• • 5. BMI: 18-30 kg/m2 ;
• • 6. Those who signed the informed consent form and volunteered to participate in this trial
• Exclusion Criteria:
• • 1. Patients with known or suspected genetic susceptibility to malignant hyperthermia;
• • 2. Patients with history of asthma;
• • 3. Patients with severe heart diseases (NYHA ≥ III, severe arrhythmia, etc.) and cerebral or pulmonary diseases, liver or kidney dysfunction; or with unstable vital signs;
• • 4. Patients with history of long-term narcotic analgesics application, including sedative and antidepressant drugs;
• • 5. Patients with history of psychotropic drug abuse within 3 months;
• • 6. Patients with long-term alcohol abuse;
• • 7. People with mental disorder and unable to communicate normally;